Chromosomal Instability and Intratumoral Heterogeneity in Glioblastoma: Mechanisms of Stemness and Therapeutic Resistance

Chromosomal instability (CIN) functions as a critical driver of adaptive evolution within glioblastoma (GBM). By facilitating the acquisition of oncogenic alterations—such as EGFR amplification, PTEN loss, and TP53 mutations—CIN exacerbates intratumoral heterogeneity and promotes aggressive tumor progression. Advanced methodologies for investigating these mechanisms often rely on precise single-cell analysis protocols to map clonal selection and karyotypic configurations. Once established, glioblastoma stem cells (GSCs) further perpetuate this diversity through asymmetrical division and lineage plasticity, enabling rapid phenotypic switching in response to therapeutic pressure.

Expression of Surface Markers in Aneuploid GSCs

The expression of GSC-associated surface markers is inherently heterogeneous and does not exhibit a uniform correlation with chromosomal ploidy status. Functional stem-cell properties in GBM are defined more accurately by tumor-initiating capacity and underlying transcriptional programs than by individual surface markers. Table 1 summarizes the variable expression profiles observed in GSC populations with chromosomal aberrations.

Molecular Pathophysiology and Signaling Networks

GBM pathogenesis is tightly linked to specific molecular lesions. While IDH-mutant tumors often exhibit distinct epigenetic landscapes, IDH-wildtype GBMs are frequently characterized by RTK family mutations and mesenchymal phenotypic shifts. The interplay between CIN and the Epithelial–Mesenchymal Transition (EMT) creates a feed-forward loop that enhances malignancy. This process is reinforced by the dysregulation of key transcription factors and kinases, such as SOX2, Nestin, and AXL. Furthermore, CIN-driven intrinsic cellular stress activates the STAT3 and NF-κB pathways, which significantly augment the self-renewal and invasive potential of these cells.

Metabolic reprogramming, particularly the accumulation of the oncometabolite D-2HG in IDH-mutant gliomas, further dictates cellular fate. By inhibiting α-ketoglutarate–dependent enzymes, D-2HG induces a hypermethylated G-CIMP phenotype, which effectively "locks" cells into a progenitor-like state. Structural insights into the proteins governed by these metabolic and epigenetic shifts, such as those found in high-resolution protein models , remain essential for understanding the molecular basis of these signaling interactions.

Therapeutic Challenges and the Impact of CIN

Despite multidisciplinary clinical approaches, the prognosis for GBM remains poor, largely due to resistance to Temozolomide (TMZ) and targeted inhibitors. Resistance mechanisms are multifaceted, involving MGMT-mediated DNA repair, microRNA-dependent regulation, and the inherent genomic diversity generated by CIN. Because CIN allows cancer cells to bypass oncogene dependency—such as the heterogeneous expression of EGFRvIII—targeted therapies often face failure in clinical settings. Ultimately, CIN-driven karyotypic diversity serves as a dynamic engine for therapeutic failure, providing a constant reservoir of adaptive clones that enable tumor recurrence and progression.